Flow limitation: an overview
- PMID: 10546481
Flow limitation: an overview
Abstract
Expiratory flow limitation (EFL) refers to a functional condition in which expiratory flow cannot increase and, hence, is maximal under the prevailing conditions. Many factors, alone or combined, may cause EFL. Among them, airway obstruction, expiratory flow rate and body posture are the most important. EFL normally occurs during the forced expiratory manoeuvre after peak expiratory flow. However, its presence during tidal breathing either throughout exercise or at rest, initially in the supine and then in the seated position, is an abnormal finding which reflects progressively greater mechanical impairment. EFL promotes dynamic pulmonary hyperinflation (DH) by prolonging the time required for the respiratory system to reach its relaxation volume during expiration. Moreover, in the presence of EFL, any increase in expiratory flow can be accomplished only by raising the end-expiratory lung volume allowing tidal breathing to occur at a higher absolute lung volume. This mechanism, however, besides being physically limited, leads to an increment in DH and intrinsic end-expiratory alveolar pressure, adding an increasing threshold load on the inspiratory muscles, which become functionally weaker, and eliciting dyspnoea. In advanced chronic obstructive pulmonary disease, bronchodilators and lung volume reduction surgery do not usually reverse expiratory flow limitation, but they appear to be useful because they often allow expiratory flow limitation to occur at a lower absolute lung volume, thus reducing dynamic pulmonary hyperinflation and limiting exertional dyspnoea.
Similar articles
-
Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest.Thorax. 2002 Jun;57(6):528-32. doi: 10.1136/thorax.57.6.528. Thorax. 2002. PMID: 12037229 Free PMC article.
-
[Relationship between expiratory muscle dysfunction and dynamic hyperinflation in advanced chronic obstructive pulmonary disease].Arch Bronconeumol. 2009 Oct;45(10):487-95. doi: 10.1016/j.arbres.2009.05.011. Epub 2009 Jul 23. Arch Bronconeumol. 2009. PMID: 19631439 Spanish.
-
Does expiratory flow limitation predict chronic dyspnoea in adults with cystic fibrosis?Eur Respir J. 2006 Jul;28(1):96-101. doi: 10.1183/09031936.06.00122105. Epub 2006 Mar 15. Eur Respir J. 2006. PMID: 16540499
-
[Physiopathology of acute respiratory failure in COPD and asthma].Minerva Anestesiol. 2001 Apr;67(4):198-205. Minerva Anestesiol. 2001. PMID: 11376510 Review. Italian.
-
Physiological techniques for detecting expiratory flow limitation during tidal breathing.Eur Respir Rev. 2011 Sep 1;20(121):147-55. doi: 10.1183/09059180.00001911. Eur Respir Rev. 2011. PMID: 21881143 Free PMC article. Review.
Cited by
-
Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2000;2002(2):CD001495. doi: 10.1002/14651858.CD001495. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2000;(3):CD001495. doi: 10.1002/14651858.CD001495. PMID: 10796652 Free PMC article. Updated.
Publication types
MeSH terms
LinkOut - more resources
Medical